Either you have JavaScript disabled or your browser does not support Javascript . To work properly, this page requires JavaScript to be enabled.
How to enable JavaScript in your browser?

Ubidecarenone - Berg Pharma

Drug Profile

Ubidecarenone - Berg Pharma

Alternative Names: API-31510; BP 31510; BPM-31510; C-31510; c31510; Coenzyme Q10 - Cytotech; Coenzyme Q10 injectable nanosuspension; CoQ10 - Cytotech; Ubiquinone injectable nanosuspension

Latest Information Update: 28 Sep 2018

Price : $50 *
* Final gross price and currency may vary according to local VAT and billing address.
* Your purchase entitles you to full access to the information contained in our drug profile at the time of purchase. A link to download a PDF version of the drug profile will be included in your email receipt. Adis is an information provider. We do not sell or distribute the pharmaceutical compounds written about in this database.

At a glance

  • Originator Cytotech Labs
  • Developer Berg Pharma; National Cancer Institute (USA); Stanford University; University of Miami
  • Class Antihyperlipidaemics; Antineoplastics; Benzoquinones; Cardiotonics; Cardiovascular therapies; Coenzymes; Small molecules
  • Mechanism of Action Antioxidants; Apoptosis stimulants; Electron transport chain complex protein modulators; Proto-oncogene protein c-bcl-2 modulators
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

    Yes - Epidermolysis bullosa; Pancreatic cancer
  • New Molecular Entity No

Highest Development Phases

  • Phase II Pancreatic cancer; Squamous cell cancer
  • Phase I/II Glioma
  • Phase I Epidermolysis bullosa
  • Preclinical Glioblastoma
  • No development reported Solid tumours
  • Discontinued Basal cell cancer; Leukaemia; Lung cancer; Wounds

Most Recent Events

  • 28 Sep 2018 No recent reports of development identified for phase-I development in Solid-tumours(Combination therapy, Inoperable/Unresectable, Metastatic disease) in USA (IV, Infusion)
  • 28 Sep 2018 No recent reports of development identified for phase-I development in Solid-tumours(Inoperable/Unresectable, Metastatic disease, Monotherapy) in USA (IV, Infusion)
  • 26 Sep 2018 Discontinued - Phase-II for Basal cell cancer in USA (Topical) (Berg Pharma pipeline, September 2018)
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top